Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Day One Biopharmaceuticals, Inc. (DAWN) had Income from Continuous Operations of $-107.32M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$158.18M |
|
$-107.32M |
|
$17.21M |
|
$140.97M |
|
$285.93M |
|
$-127.75M |
|
$18.45M |
|
$-109.30M |
|
$-109.30M |
|
$-107.32M |
|
|
Income from Continuous Operations |
$-107.32M |
$-107.32M |
|
$-107.32M |
|
$-127.75M |
|
$-123.96M |
|
103.21M |
|
103.21M |
|
$-1.04 |
|
$-1.04 |
|
| Balance Sheet Financials | |
$485.10M |
|
$2.14M |
|
$22.73M |
|
$507.83M |
|
$60.52M |
|
-- |
|
$6.14M |
|
$66.67M |
|
$441.16M |
|
$423.14M |
|
$441.16M |
|
102.98M |
|
| Cash Flow Statement Financials | |
$-103.76M |
|
$174.65M |
|
$1.22M |
|
$124.97M |
|
$197.08M |
|
$72.11M |
|
$44.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
89.12% |
|
-80.76% |
|
-80.76% |
|
-78.37% |
|
-69.10% |
|
-67.85% |
|
$-104.05M |
|
-- |
|
-- |
|
-- |
|
0.31 |
|
2.72 |
|
5.92 |
|
61.69 |
|
-24.33% |
|
-25.36% |
|
-21.13% |
|
-24.33% |
|
$4.28 |
|
$-1.01 |
|
$-1.01 |
|